01 — At a Glance
The Pharma Darling That Broke Its Own China. For Now.
- 52-Week High / Low₹2,727 / ₹2,012
- 9M FY26 Revenue₹10,835 Cr
- 9M FY26 PAT₹1,379 Cr
- Q3 FY26 EPS₹9.90
- Annualised EPS (Q3×4)₹39.60
- Book Value₹370
- Price to Book5.91x
- Dividend Yield0.05%
- Debt / Equity0.55x
- Profit Growth (TTM)-9%
Auditor’s Opening Note: Mankind Pharma posted ₹3,567 crore Q3 revenue (+11.5% YoY), but PAT at ₹414 crore shows a messy story. The company is India’s #1 by prescriptions, #2 by volume in IPM, yet profit margins compressed due to R&D spend, labour code adoption, and a brutal internal “transformation” that management admits went wrong. The 9M growth is 18.7% revenue but -9% profit (TTM). The stock trades at 48.6x P/E — over 75% premium to industry median. Chronic therapies are growing 15%+. Acute therapies are in ICU. BSV acquisition for ₹13,768 crore is still being digested. Fasten your seatbelt.
02 — Introduction
The Prescription Powerhouse That Forgot How to Count
Mankind Pharma. Founded in 1995. #1 in prescription volume for eight consecutive years. Over ₹500 crore in branded formulations revenue. A field force of 18,000+. Presence in 50+ acute and chronic therapeutic areas across India. Four consumer healthcare brands ranked #1 in their categories. It’s the kind of company that gets featured in textbooks on how to build a distribution moat.
So what went wrong? On the February 2026 concall, management did something rare for Indian pharma CEOs: it admitted fault. CEO Rajeev Juneja described a “major kind of transformation” over the last 12–18 months involving 20–25% of the field force being cycled through (fired, quit, or reassigned). The stated reason? Cultural integration gone sideways during the shift toward a chronic-focused model. The honest quote: “We overestimated our power of executing.” Translation: We broke morale, good people left, relationship-dependent acute segments tanked, and now we’re rebuilding.
Chronic therapies are doing great — cardiovascular +16.7% YoY in Q3, anti-diabetes +14.4% YoY. But acute — the bread-and-butter for relationship-driven prescription sales — is still limping. The stock response? Up marginally, then down. The market priced in execution risk, and rightfully so. The question now is whether the disruption is behind or ahead.
In the meantime, the company spent ₹13,768 crore acquiring the women’s health portfolio from Bharat Serums and Vaccines (BSV). One of the largest pharma M&A deals in Indian history. The thesis: access to specialty, women’s health, and critical care therapies. The execution risk: integrating a new business while fixing your core engine. All of this while balancing a P/E of 48.6x, which prices in perfection.
Management Concall (Feb 2026): “There are no targets. We believe only in daily sales… not weekly… prescription is sale. That’s all. Rest all is farce.” — Rajeev Juneja. Translation: Mankind operates like a startup in a controlled chaos mode. It works until it doesn’t.
03 — Business Model: Rx Pills, Consumer Condoms, Export Dreams
Where Does the Cash Actually Come From?
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
